Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DRALZINE vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dralzine is a direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased systemic vascular resistance and afterload. The exact molecular mechanism is not fully elucidated but involves inhibition of calcium influx and interference with the contractile process.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Essential hypertension (off-label),Hypertensive crisis (off-label)
Hypertension
Oral: 50-100 mg twice daily; maximum 200 mg/day.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Terminal elimination half-life is 2-5 hours in patients with normal renal function; prolonged to 10-20 hours in renal impairment.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Primarily hepatic via N-acetyltransferase (NAT2); exhibits polymorphic acetylation. Metabolites include hydralazine pyruvate hydrazone and other hydrazone derivatives.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Primarily renal (70-90% as unchanged drug and metabolites); biliary/fecal excretion accounts for <10%.
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
85-90%, primarily to albumin.
Approximately 70-80% bound to plasma proteins, primarily albumin.
1.5-2.0 L/kg; indicates extensive tissue distribution, exceeding total body water.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral: 30-50% due to first-pass metabolism.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
GFR 10-50 m L/min: 50 mg twice daily; GFR <10 m L/min: 50 mg once daily.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg twice daily; Child-Pugh C: avoid use.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
1-2 mg/kg/day divided every 12 hours; maximum 5 mg/kg/day.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Initiate at 25 mg twice daily; titrate slowly to avoid hypotension.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None.
None.
May induce a lupus-like syndrome, especially in slow acetylators; monitor for symptoms such as arthralgia, fever, and rash.,May cause drug-induced autoimmune hepatitis.,Can precipitate angina or myocardial infarction in patients with coronary artery disease.,Risk of hypotension and reflex tachycardia.
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Hypersensitivity to hydralazine or components,Coronary artery disease (relative contraindication due to risk of myocardial ischemia),Mitral valve rheumatic heart disease (relative),Idiopathic lupus erythematosus
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
DRALZINE should be taken with or without food, but consistent timing is recommended. High-tyramine foods (e.g., aged cheeses, cured meats, fermented products) may increase the risk of hypertensive crisis in patients also taking MAOIs; however, interactions with food are otherwise minimal. Avoid large, high-fat meals as they may affect absorption.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
First trimester: No evidence of teratogenicity in human studies; however, consider fetal hypotension and impaired uteroplacental perfusion. Second and third trimesters: Risk of fetal hypotension, adverse fetal heart rate patterns, and neonatal adverse effects (hypotension, tachycardia, fluid retention).
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Compatible with breastfeeding. M/P ratio not established; drug appears in breast milk in low amounts (<1% maternal dose). No reported adverse effects in infants.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
No specific dose adjustments required based on pharmacokinetic changes in pregnancy. However, because of increased blood volume, higher doses may be needed to achieve same antihypertensive effect; titrate to target blood pressure.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
DRALZINE (hydralazine) is a direct-acting vasodilator used primarily for hypertension, especially in pregnancy (pre-eclampsia). It can cause a drug-induced lupus-like syndrome, especially in slow acetylators; monitor for arthralgias, rash, and positive ANA. Tachycardia is a common reflex response; often co-administered with a beta-blocker. Avoid in patients with coronary artery disease, high-output heart failure, or mitral valve rheumatic heart disease.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take exactly as prescribed; do not skip doses or double up.,You may experience dizziness or lightheadedness, especially when standing up; rise slowly and avoid sudden position changes.,Report any joint pain, rash, fever, or chest pain to your healthcare provider immediately.,Avoid alcohol, which can worsen side effects like dizziness and low blood pressure.,Do not stop taking this medication abruptly; sudden withdrawal can cause a rapid increase in blood pressure.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DRALZINE vs ALDOCLOR-150, answered by our medical review team.
DRALZINE is a Antihypertensive that works by Dralzine is a direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased systemic vascular resistance and afterload. The exact molecular mechanism is not fully elucidated but involves inhibition of calcium influx and interference with the contractile process.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DRALZINE and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DRALZINE is: Oral: 50-100 mg twice daily; maximum 200 mg/day.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DRALZINE and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DRALZINE is classified as Category C. First trimester: No evidence of teratogenicity in human studies; however, consider fetal hypotension and impaired uteroplacental perfusion. Second and third trimesters: Risk of fet. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.